CoChat

Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression

Open access
Wang, Qi, Su, Lishan · 2019 · mBio

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

How Vpr enhances HIV-1 replication in macrophages is still unclear. We report here that Vpr enhanced HIV-1 Env processing during the first round of HIV-1 replication, resulting in virions with higher Env incorporation and viral infectivity. These higher-quality viral particles contributed to elevated infection during the second round and spreading infection in macrophages and other HIV-1 target cells. We have recently discovered that TET2 is a novel host factor degraded by Vpr, which leads to sustained IL-6 expression in macrophages. Interestingly, Vpr-enhanced HIV-1 Env processing depended on both the IFITIM3 and TET2 genes. The constitutive expression of IFITIM3 expression in macrophages was maintained by TET2, which demethylated the IFITIM3 promoter. We conclude that the Vpr degrades TET2 to enhance HIV-1 replication in macrophages by reducing IFITIM3 expression to increase viral Env processing, virion incorporation, and infectivity and by sustaining IL-6 expression to increase HIV-1 gene expression. The Vpr-TET2 axis may serve as a novel target to develop anti-HIV drugs to inhibit HIV-1 infection and pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.01344-19

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Vpr enhances Env processing and virion infectivity in MDMs. (A) Vpr has no effect on first-round HIV-1 replication in macrophages. MDMs were infected with HIV-1 or HIV-1 ΔVpr viruses (MOI = 0.1). Levels of p24 in the supernatant were assessed at 2 and 4 dpi. Cells were treated with 2 μM nevirapine (NVP) at 2 dpi, where indicated, to inhibit the second round of HIV-1 infection. (B) Vpr enhances HIV-1 Env processing in macrophages. Shown are Western blots of cell lysates from MDMs infected with HIV-1 for 4 days, with NVP added at 2 dpi. Env proteins gp160 and gp120 were detected with anti-gp120 antibody, gp41 was detected by anti-gp41 antibody, p24 was detected by anti-p24 antibody, and actin was detected by antiactin antibody. Samples diluted 1× or 2× were tested as indicated. (C) Vpr-enhanced gp120/gp160 and gp120/p24 ratios in MDMs are summarized with MDMs from three independent experiments with three different donors. (D) Vpr enhances Env incorporation in virions from MDMs. Viral supernatants were concentrated from MDMs infected with HIV-1 or HIV-1 ΔVpr viruses at 2 dpi by ultracentrifugation (over 20% sucrose). Western blotting was performed by anti-gp120, -p24, and -gp41 antibodies. (E) Vpr-enhanced gp120/p24 ratios and gp41/p24 ratios in virions produced from MDMs are summarized from two different donors. (F and G) Vpr enhances specific infectivity of virions from MDMs. (F) Supernatants with equal amounts of p24 from MDMs infected with wild-type HIV-1 or HIV-1 ΔVpr viruses were used to infect TZM-bl indicator cells. Luciferase activity was measured at 48 hpi. Data (luciferase/ng p24) from three wells were used from each donor MDM, and 3 technical repeats were performed with supernatant from each well. MDMs derived from 3 donors (n = 3) were used to repeat the experiments. Shown are the mean values of MDMs from 3 donors. **, P < 0.01 by nonparametric one-way analysis of variance (ANOVA). (G) Supernatants with equal amounts of p24 from MDMs infected with wild-type HIV-1 or HIV-1 ΔVpr viruses were used to infect indicator MAGI-CCR5 cells. Infectivity represents infectious units (IU) per ng p24. Values are average IU/p24 from three independent experiments with MDMs from three donors.
FIG 1 Vpr enhances Env processing and virion infectivity in MDMs. (A) Vpr has no effect on first-round HIV-1 replication in macrophages. MDMs were infected with HIV-1 or HIV-1 ΔVpr viruses (MOI = 0.1). Levels of p24 in the supernatant were assessed at 2 and 4 dpi. Cells were treated with 2 μM nevirapine (NVP) at 2 dpi, where indicated, to inhibit the second round of HIV-1 infection. (B) Vpr enhances HIV-1 Env processing in macrophages. Shown are Western blots of cell lysates from MDMs infected with HIV-1 for 4 days, with NVP added at 2 dpi. Env proteins gp160 and gp120 were detected with anti-gp120 antibody, gp41 was detected by anti-gp41 antibody, p24 was detected by anti-p24 antibody, and actin was detected by antiactin antibody. Samples diluted 1× or 2× were tested as indicated. (C) Vpr-enhanced gp120/gp160 and gp120/p24 ratios in MDMs are summarized with MDMs from three independent experiments with three different donors. (D) Vpr enhances Env incorporation in virions from MDMs. Viral supernatants were concentrated from MDMs infected with HIV-1 or HIV-1 ΔVpr viruses at 2 dpi by ultracentrifugation (over 20% sucrose). Western blotting was performed by anti-gp120, -p24, and -gp41 antibodies. (E) Vpr-enhanced gp120/p24 ratios and gp41/p24 ratios in virions produced from MDMs are summarized from two different donors. (F and G) Vpr enhances specific infectivity of virions from MDMs. (F) Supernatants with equal amounts of p24 from MDMs infected with wild-type HIV-1 or HIV-1 ΔVpr viruses were used to infect TZM-bl indicator cells. Luciferase activity was measured at 48 hpi. Data (luciferase/ng p24) from three wells were used from each donor MDM, and 3 technical repeats were performed with supernatant from each well. MDMs derived from 3 donors (n = 3) were used to repeat the experiments. Shown are the mean values of MDMs from 3 donors. **, P < 0.01 by nonparametric one-way analysis of variance (ANOVA). (G) Supernatants with equal amounts of p24 from MDMs infected with wild-type HIV-1 or HIV-1 ΔVpr viruses were used to infect indicator MAGI-CCR5 cells. Infectivity represents infectious units (IU) per ng p24. Values are average IU/p24 from three independent experiments with MDMs from three donors.CC BY · PubMed Central
FIG 2 IFITM3 is constitutively expressed in MDMs via TET2-dependent mechanisms. (A) Relative gene expression of HIV-1 restriction factors in MDMs derived from 4 donors is summarized. (B) MDMs were transduced with lentiviral vectors encoding control shRNA or with TET2 shRNA. Relative expression of restriction factors with detectable expression in MDMs, including Serinc3, Serinc 5, Trim 5a, SAMHD1, tetherin, and IFITM3, was measured. (C) TET2 and IFITM3 were detected with anti-TET2 antibody and anti-IFITM3 antibody by Western blotting with cell lysates from MDMs transduced with control shRNA, TET2 shRNA, and IFITM3 shRNA. (D) TET2 (left panel) and IFITM3 (right panel) mRNAs were detected by RT-qPCR in MDMs transduced with control, TET2, and IFITM3 shRNA. * and ** indicate P < 0.05 and P < 0.01, respectively.
FIG 2 IFITM3 is constitutively expressed in MDMs via TET2-dependent mechanisms. (A) Relative gene expression of HIV-1 restriction factors in MDMs derived from 4 donors is summarized. (B) MDMs were transduced with lentiviral vectors encoding control shRNA or with TET2 shRNA. Relative expression of restriction factors with detectable expression in MDMs, including Serinc3, Serinc 5, Trim 5a, SAMHD1, tetherin, and IFITM3, was measured. (C) TET2 and IFITM3 were detected with anti-TET2 antibody and anti-IFITM3 antibody by Western blotting with cell lysates from MDMs transduced with control shRNA, TET2 shRNA, and IFITM3 shRNA. (D) TET2 (left panel) and IFITM3 (right panel) mRNAs were detected by RT-qPCR in MDMs transduced with control, TET2, and IFITM3 shRNA. * and ** indicate P < 0.05 and P < 0.01, respectively.CC BY · PubMed Central
FIG 3 Vpr enhances Env processing/infectivity in MDMs via TET2- and IFITM3-dependent mechanisms. (A) MDMs transduced with lentiviral vectors with shRNA-mediated knockdown of TET2 and IFITM3 were infected with HIV-1 or HIV-1 ΔVpr viruses as described above. Western blot analysis of cell lysates was performed as in Fig. 1B. The gp120/gp160 ratio of HIV-1 from control MDMs is defined as 100%. (B) MDMs were transduced with lentivirus vectors with control shRNA, shTET2, and shIFITM3. Viral particles were purified by ultracentrifugation (over 20% sucrose) from the aforementioned MDMs infected with HIV-1 or HIV-1 ΔVpr viruses for 4 days, with NVP added at 2 dpi. Five nanograms of p24 per virion for each sample was added per lane for analysis of gp120, p24, and gp41 in virions. Western blotting was performed by using anti-gp120, p24, and gp41 antibodies. (C) The ratios of gp120/p24 and of gp41/p24 are summarized from three different donors. (D) Supernatants from MDMs infected with HIV-1 or HIV-1 ΔVpr viruses were used to infect TZM-bl indicator cells. The relative infectivity is defined as HIV-induced luciferase/ng (n = 3 donors).
FIG 3 Vpr enhances Env processing/infectivity in MDMs via TET2- and IFITM3-dependent mechanisms. (A) MDMs transduced with lentiviral vectors with shRNA-mediated knockdown of TET2 and IFITM3 were infected with HIV-1 or HIV-1 ΔVpr viruses as described above. Western blot analysis of cell lysates was performed as in Fig. 1B. The gp120/gp160 ratio of HIV-1 from control MDMs is defined as 100%. (B) MDMs were transduced with lentivirus vectors with control shRNA, shTET2, and shIFITM3. Viral particles were purified by ultracentrifugation (over 20% sucrose) from the aforementioned MDMs infected with HIV-1 or HIV-1 ΔVpr viruses for 4 days, with NVP added at 2 dpi. Five nanograms of p24 per virion for each sample was added per lane for analysis of gp120, p24, and gp41 in virions. Western blotting was performed by using anti-gp120, p24, and gp41 antibodies. (C) The ratios of gp120/p24 and of gp41/p24 are summarized from three different donors. (D) Supernatants from MDMs infected with HIV-1 or HIV-1 ΔVpr viruses were used to infect TZM-bl indicator cells. The relative infectivity is defined as HIV-induced luciferase/ng (n = 3 donors).CC BY · PubMed Central
FIG 4 The Vpr-TET2 axis enhances HIV-Yu-2 Env processing and virion infectivity in MDMs. (A) MDMs were infected with Yu-2 or Yu-2 ΔVpr viruses (MOI = 0.1). Levels of p24 in the supernatant were assessed at 2 and 4 dpi. Cells were treated with 2 μM nevirapine (NVP) at 2 dpi where indicated, to inhibit the second round of HIV-Yu-2 infection. (B) Western blots of cell lysates from MDMs infected with Yu-2 or Yu-2 ΔVpr for 4 days with NVP added at 2 dpi. Env proteins gp160 and gp120 were detected with anti-gp120 antibody, gp41 was detected with anti-gp41 antibody, and p24 was detected with anti-p24 antibody. (C) Vpr-enhanced gp120/p24 and gp120/gp160 ratios in MDMs are summarized with MDMs from with two different donors. (D) Viral supernatants were concentrated from MDMs infected with Yu-2 or Yu-2 ΔVpr viruses at 2 dpi by ultracentrifugation (over 20% sucrose). Western blotting was performed by using anti-gp120, -p24, and -gp41 antibodies. (E) Vpr-enhanced gp120/p24 ratios are summarized from two different donors. (F) Supernatants with equal amounts of p24 from MDMs infected with Yu-2 or Yu-2 ΔVpr viruses were used to infect TZM-bl indicator cells. Luciferase activity was measured at 48 hpi. Data (luciferase/ng p24) from three wells were used from each donor MDM, and 3 technical repeats were performed with supernatant from each well. MDMs derived from 2 donors were used to repeat the experiments. (G) MDMs were transduced with control shRNA, shTET2, and shIFITM3. Viral supernatants were concentrated from the aforementioned MDMs infected with Yu-2 or Yu-2 ΔVpr viruses for 4 days, with NVP added at 2 dpi, by ultracentrifugation (over 20% sucrose). Five nanograms of p24 for each virion was added per lane for analysis of gp120, p24, and gp41 in virions. (H) Supernatants from MDMs infected with Yu-2 or Yu-2 ΔVpr viruses were used to infect TZM-bl indicator cells. The relative infectivity is defined by HIV-induced luciferase activity per ng of p24. Supernatant from control MDMs infected with HIV-YU-2 is defined as 100% (n = 2 donors).
FIG 4 The Vpr-TET2 axis enhances HIV-Yu-2 Env processing and virion infectivity in MDMs. (A) MDMs were infected with Yu-2 or Yu-2 ΔVpr viruses (MOI = 0.1). Levels of p24 in the supernatant were assessed at 2 and 4 dpi. Cells were treated with 2 μM nevirapine (NVP) at 2 dpi where indicated, to inhibit the second round of HIV-Yu-2 infection. (B) Western blots of cell lysates from MDMs infected with Yu-2 or Yu-2 ΔVpr for 4 days with NVP added at 2 dpi. Env proteins gp160 and gp120 were detected with anti-gp120 antibody, gp41 was detected with anti-gp41 antibody, and p24 was detected with anti-p24 antibody. (C) Vpr-enhanced gp120/p24 and gp120/gp160 ratios in MDMs are summarized with MDMs from with two different donors. (D) Viral supernatants were concentrated from MDMs infected with Yu-2 or Yu-2 ΔVpr viruses at 2 dpi by ultracentrifugation (over 20% sucrose). Western blotting was performed by using anti-gp120, -p24, and -gp41 antibodies. (E) Vpr-enhanced gp120/p24 ratios are summarized from two different donors. (F) Supernatants with equal amounts of p24 from MDMs infected with Yu-2 or Yu-2 ΔVpr viruses were used to infect TZM-bl indicator cells. Luciferase activity was measured at 48 hpi. Data (luciferase/ng p24) from three wells were used from each donor MDM, and 3 technical repeats were performed with supernatant from each well. MDMs derived from 2 donors were used to repeat the experiments. (G) MDMs were transduced with control shRNA, shTET2, and shIFITM3. Viral supernatants were concentrated from the aforementioned MDMs infected with Yu-2 or Yu-2 ΔVpr viruses for 4 days, with NVP added at 2 dpi, by ultracentrifugation (over 20% sucrose). Five nanograms of p24 for each virion was added per lane for analysis of gp120, p24, and gp41 in virions. (H) Supernatants from MDMs infected with Yu-2 or Yu-2 ΔVpr viruses were used to infect TZM-bl indicator cells. The relative infectivity is defined by HIV-induced luciferase activity per ng of p24. Supernatant from control MDMs infected with HIV-YU-2 is defined as 100% (n = 2 donors).CC BY · PubMed Central
FIG 5 Vpr degrades TET2 to reduce demethylation of the IFITM3 promoter in MDMs. (A and B) TET2 is required for the constitutive expression of IFITM3 in MDMs. (A) Western blot analysis of cell lysates was performed with anti-TET2 or anti-IFITM3 antibody. Relative IFITM3 expression is calculated as IFITM3/actin ratios. (B) MDMs with control or TET2 shRNA were treated with VLPs with or without Vpr for 24 h. TET2 and IFITM3 mRNA levels were detected by RT-qPCR. (C and D) TET2 binds to the IFITM3 promoter to catalyze its demethylation. (C) MDMs transduced with control or TET2 shRNA were treated with VLPs with or without Vpr for 24 h. The ChIP assay was performed with anti-TET2 monoclonal antibody (MAb) to determine TET2 binding to the IFITM3 promoter. (D) ChIP with anti-5hmC MAb was performed to determine demethylation at the IFITM3 promoter. Specific IFITM3 promoter DNA by ChIP is normalized to the DNA ChIP with control IgG. DNA ChIP with control IgG is defined as 1. * and ** indicate P < 0.05 and P < 0.01, respectively. (E) Schematic diagram of TET2-mediated demethylation of the IFITM3 promoter.
FIG 5 Vpr degrades TET2 to reduce demethylation of the IFITM3 promoter in MDMs. (A and B) TET2 is required for the constitutive expression of IFITM3 in MDMs. (A) Western blot analysis of cell lysates was performed with anti-TET2 or anti-IFITM3 antibody. Relative IFITM3 expression is calculated as IFITM3/actin ratios. (B) MDMs with control or TET2 shRNA were treated with VLPs with or without Vpr for 24 h. TET2 and IFITM3 mRNA levels were detected by RT-qPCR. (C and D) TET2 binds to the IFITM3 promoter to catalyze its demethylation. (C) MDMs transduced with control or TET2 shRNA were treated with VLPs with or without Vpr for 24 h. The ChIP assay was performed with anti-TET2 monoclonal antibody (MAb) to determine TET2 binding to the IFITM3 promoter. (D) ChIP with anti-5hmC MAb was performed to determine demethylation at the IFITM3 promoter. Specific IFITM3 promoter DNA by ChIP is normalized to the DNA ChIP with control IgG. DNA ChIP with control IgG is defined as 1. * and ** indicate P < 0.05 and P < 0.01, respectively. (E) Schematic diagram of TET2-mediated demethylation of the IFITM3 promoter.CC BY · PubMed Central
FIG 6 The Vpr-TET2 axis independently enhances HIV-1 replication through reduced IFITM3 and sustained IL-6 expression. (A) Vpr-enhanced Env processing is independent of IL-6 signaling. MDMs were infected with HIV-1 or HIV-1 ΔVpr viruses for 4 days, with NVP added at 2 dpi, and treated with the isotype control or anti-IL-6 neutralizing antibody. Western blots were performed with cell lysates. Env proteins gp160 and gp120 were detected with anti-gp120 antibody, gp41 was detected by anti-gp41 antibody, and p24 was detected by anti-p24 antibody. gp120/p24 and gp120/gp160 ratios are shown. (B) MDMs transduced with control shRNA, shTET2, and shIFITM3 were infected with HIV-1 or HIV-1 ΔVpr and treated with the isotype control or anti-IL-6 neutralizing antibody. p24 levels in the supernatant were measured at 6 dpi. (C) Relative ability of Vpr to enhance HIV-1 replication in cells treated with the isotype control and anti-IL-6 neutralizing antibody at day 6. Data from two different donors are summarized by setting Vpr-enhanced replication in isotype control MDMs transduced with control shRNA at 1.0. * indicates P < 0.05. (D) The Vpr-TET2 axis enhances HIV-1 replication in macrophages independently by modulating expression of IFITM3 and IL-6 during HIV-1 infection.
FIG 6 The Vpr-TET2 axis independently enhances HIV-1 replication through reduced IFITM3 and sustained IL-6 expression. (A) Vpr-enhanced Env processing is independent of IL-6 signaling. MDMs were infected with HIV-1 or HIV-1 ΔVpr viruses for 4 days, with NVP added at 2 dpi, and treated with the isotype control or anti-IL-6 neutralizing antibody. Western blots were performed with cell lysates. Env proteins gp160 and gp120 were detected with anti-gp120 antibody, gp41 was detected by anti-gp41 antibody, and p24 was detected by anti-p24 antibody. gp120/p24 and gp120/gp160 ratios are shown. (B) MDMs transduced with control shRNA, shTET2, and shIFITM3 were infected with HIV-1 or HIV-1 ΔVpr and treated with the isotype control or anti-IL-6 neutralizing antibody. p24 levels in the supernatant were measured at 6 dpi. (C) Relative ability of Vpr to enhance HIV-1 replication in cells treated with the isotype control and anti-IL-6 neutralizing antibody at day 6. Data from two different donors are summarized by setting Vpr-enhanced replication in isotype control MDMs transduced with control shRNA at 1.0. * indicates P < 0.05. (D) The Vpr-TET2 axis enhances HIV-1 replication in macrophages independently by modulating expression of IFITM3 and IL-6 during HIV-1 infection.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 39

Metadata

Authors
Wang, Q., & Su, L.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Su, Lishan
Venue
mBio
Published
2019-08-27
Volume
10
Issue
4
ISSN
  • 2150-7511 (ISSN-L)
  • 2161-2129
OpenAlex
W2969404469
Cited by
34
References
51
Citations by year
2026: 5 · 2025: 3 · 2024: 6 · 2023: 1 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 2
FWCI
2.66
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UNC Libraries
Funders
HHS | National Institutes of Health (AI127346, AI136990)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
Keywords
HIV-1 Vpr, TET2, IFITM3, viral infectivity, macrophages, viral assembly, interleukin-6, promoter demethylation, host factors, HIV-1 replication, anti-HIV drug targets
MeSH terms
DNA Demethylation, Carrier Proteins, Cell Line, DNA-Binding Proteins, Humans, Macrophages, Membrane Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, Virion, Virus Replication, HIV-1, Interleukin-6, Gene Expression Regulation, Viral, RNA-Binding Proteins, Anti-HIV Agents, Dioxygenases, env Gene Products, Human Immunodeficiency Virus, vpr Gene Products, Human Immunodeficiency Virus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression. https://app.cochat.ai/papers/10.1128/mbio.01344-19
The paper
Wang, Q., & Su, L. (2019). Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression. mBio. https://doi.org/10.1128/mbio.01344-19

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.